Cytotoxic T Lymphocyte Protein 4-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Cytotoxic T Lymphocyte Protein 4-Pipeline Review H2 2017” this report provides an comprehensive report Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)-Pipel
(EMAILWIRE.COM, September 01, 2017 ) Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)-CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 4, 18, 8 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Hodgkin Lymphoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Papillary Renal Cell Carcinoma, Peritoneal Cancer, Primitive Neuroectodermal Tumor (PNET), Renal Cell Carcinoma, Adrenal Gland Cancer, Advanced Malignancy, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal (GE) Junction Carcinomas, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Lymphoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Skin Cancer, Soft Tissue Sarcoma, Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
Furthermore, this report also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/cytotoxic-t-lymphocyte-protein-4-pipeline-review-h2-2017
Report Scope
-The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
-The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
-The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011022691/sample
Reasons to buy
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aduro BioTech Inc
Agenus Inc
Alligator Bioscience AB
Bristol-Myers Squibb Company
Cold Genesys Inc
Crown Bioscience Inc
Five Prime Therapeutics Inc
Globavir Biosciences Inc
Humorigin Biotechnology Corp
Immunocore Ltd
Immunwork Inc
Innovent Biologics Inc
JHL Biotech Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
OncoImmune Inc
Premier Biomedical Inc
Serometrix LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011022691/discount
List of Tables
Number of Products under Development by Stage of Development, H2 2017 11
Number of Products under Development by Therapy Areas, H2 2017 12
Number of Products under Development by Indications, H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Number of Products under Development by Companies, H2 2017 (Contd..1) 18
Products under Development by Companies, H2 2017 19
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 27
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 28
Number of Products under Investigation by Universities/Institutes, H2 2017 29
Products under Investigation by Universities/Institutes, H2 2017 30
Number of Products by Stage and Mechanism of Actions, H2 2017 32
Number of Products by Stage and Route of Administration, H2 2017 34
Number of Products by Stage and Molecule Type, H2 2017 36
Pipeline by Aduro BioTech Inc, H2 2017 37
Pipeline by Agenus Inc, H2 2017 38
Pipeline by Alligator Bioscience AB, H2 2017 39
Pipeline by Bristol-Myers Squibb Company, H2 2017 40
Pipeline by Cold Genesys Inc, H2 2017 43
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011022691/buy/3500
Furthermore, this report also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/cytotoxic-t-lymphocyte-protein-4-pipeline-review-h2-2017
Report Scope
-The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
-The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
-The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011022691/sample
Reasons to buy
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aduro BioTech Inc
Agenus Inc
Alligator Bioscience AB
Bristol-Myers Squibb Company
Cold Genesys Inc
Crown Bioscience Inc
Five Prime Therapeutics Inc
Globavir Biosciences Inc
Humorigin Biotechnology Corp
Immunocore Ltd
Immunwork Inc
Innovent Biologics Inc
JHL Biotech Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
OncoImmune Inc
Premier Biomedical Inc
Serometrix LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011022691/discount
List of Tables
Number of Products under Development by Stage of Development, H2 2017 11
Number of Products under Development by Therapy Areas, H2 2017 12
Number of Products under Development by Indications, H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Number of Products under Development by Companies, H2 2017 (Contd..1) 18
Products under Development by Companies, H2 2017 19
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 27
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 28
Number of Products under Investigation by Universities/Institutes, H2 2017 29
Products under Investigation by Universities/Institutes, H2 2017 30
Number of Products by Stage and Mechanism of Actions, H2 2017 32
Number of Products by Stage and Route of Administration, H2 2017 34
Number of Products by Stage and Molecule Type, H2 2017 36
Pipeline by Aduro BioTech Inc, H2 2017 37
Pipeline by Agenus Inc, H2 2017 38
Pipeline by Alligator Bioscience AB, H2 2017 39
Pipeline by Bristol-Myers Squibb Company, H2 2017 40
Pipeline by Cold Genesys Inc, H2 2017 43
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011022691/buy/3500
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results